(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 41.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Gossamer Bio's revenue in 2025 is $40,237,000.On average, 10 Wall Street analysts forecast GOSS's revenue for 2025 to be $8,622,045,313, with the lowest GOSS revenue forecast at $4,764,078,520, and the highest GOSS revenue forecast at $15,948,475,915. On average, 10 Wall Street analysts forecast GOSS's revenue for 2026 to be $10,010,658,692, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $28,745,456,590.
In 2027, GOSS is forecast to generate $28,738,635,172 in revenue, with the lowest revenue forecast at $14,499,151,913 and the highest revenue forecast at $53,759,597,386.